AMÉLIORATION DE L'EXCITATION SEXUELLE, DU DÉSIR SEXUEL, DE L'ORGASME ET/OU DU PLAISIR À LA SUITE D'UNE ADMINISTRATION DE PRASTÉRONE (DHA) INTRA VAGINALE CHEZ DES FEMMES NE SOUFFRANT PAS DE DYSPAREUNIE OU D'AUTRES SYMPTÔMES D'ATROPHIE VULVO-VAGINALE OU INDÉPENDAMMENT DE CEUX-CI
Intravaginal DHEA is used for the treatment of at least one condition selected from the group consisting of female hypoactive sexual desire disorder, female sexual arousal disorder, female orgasm disorder and female sexual interest arousal disorder in a woman who either (1) is not suffering from symptoms of vulvo-vaginal atrophy and/or (2) is not suffering from moderate to severe dyspareunia.